Literature DB >> 18285827

Novel SIL1 mutations and exclusion of functional candidate genes in Marinesco-Sjögren syndrome.

Anna-Kaisa Anttonen1, Eija Siintola, Lisbeth Tranebjaerg, Nobue K Iwata, Emilia K Bijlsma, Hiroyuki Meguro, Yaeko Ichikawa, Jun Goto, Outi Kopra, Anna-Elina Lehesjoki.   

Abstract

Marinesco-Sjögren syndrome (MSS) is a rare autosomal recessively inherited neurodegenerative disorder characterized by cerebellar ataxia, cataracts, mental retardation, and progressive myopathy. Recently, mutations in the SIL1 gene, which encodes an endoplasmic reticulum (ER) resident cochaperone, were identified as a major cause of MSS. We here report four novel mutations in SIL1, including the first missense substitution p.Leu457Pro described in MSS. In addition, we excluded three functional candidate genes, HSPA5, HYOU1, and AARS, as causative genes in SIL1 mutation-negative patients. To understand the mechanisms of disturbed SIL1 function, we studied the subcellular localization of the missense mutant Leu457Pro protein in COS-1 cells. Moreover, we studied a mutant protein lacking the putative C-terminal ER retrieval signal. In contrast to the wild-type protein's localization to ER and Golgi apparatus, both mutant proteins formed aggregates within the ER depending on the expression level. These data imply that aggregation of mutant proteins may contribute to MSS pathogenesis. The genetic background of a subgroup of patients with MSS remains uncovered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285827     DOI: 10.1038/ejhg.2008.22

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  14 in total

Review 1.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

2.  C-terminal mutations destabilize SIL1/BAP and can cause Marinesco-Sjögren syndrome.

Authors:  Jennifer Howes; Yuichiro Shimizu; Matthias J Feige; Linda M Hendershot
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

3.  Cellular Signature of SIL1 Depletion: Disease Pathogenesis due to Alterations in Protein Composition Beyond the ER Machinery.

Authors:  Andreas Roos; Laxmikanth Kollipara; Stephan Buchkremer; Thomas Labisch; Eva Brauers; Christian Gatz; Chris Lentz; José Gerardo-Nava; Joachim Weis; René P Zahedi
Journal:  Mol Neurobiol       Date:  2015-10-14       Impact factor: 5.590

Review 4.  BiP and its nucleotide exchange factors Grp170 and Sil1: mechanisms of action and biological functions.

Authors:  Julia Behnke; Matthias J Feige; Linda M Hendershot
Journal:  J Mol Biol       Date:  2015-02-16       Impact factor: 5.469

Review 5.  Movement Disorders Associated with Hypogonadism.

Authors:  Paulina Gonzalez-Latapi; Mario Sousa; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2021-07-29

6.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

7.  The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo.

Authors:  Arne A Ittner; Josefine Bertz; Tse Yan Becky Chan; Janet van Eersel; Patsie Polly; Lars M Ittner
Journal:  Diabetologia       Date:  2014-04-15       Impact factor: 10.122

8.  Sil1, a nucleotide exchange factor for BiP, is not required for antibody assembly or secretion.

Authors:  Viraj P Ichhaporia; Tyler Sanford; Jenny Howes; Tony N Marion; Linda M Hendershot
Journal:  Mol Biol Cell       Date:  2014-12-03       Impact factor: 4.138

9.  Alteration of the unfolded protein response modifies neurodegeneration in a mouse model of Marinesco-Sjögren syndrome.

Authors:  Lihong Zhao; Christine Rosales; Kevin Seburn; David Ron; Susan L Ackerman
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

10.  Novel SIL1 mutations in consanguineous Pakistani families mapping to chromosomes 5q31.

Authors:  S Amer Riazuddin; Laleh Amiri-Kordestani; Haiba Kaul; Tariq Butt; Xiaodong Jiao; Sheikh Riazuddin; J Fielding Hejtmancik
Journal:  Mol Vis       Date:  2009-05-22       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.